News|Videos|September 19, 2023

The Impact of Advanced Manufacturing Technology (PDA/FDA Joint Regulatory Conference 2023)

Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses how advanced manufacturing technology can improve things such as cost and efficiency.

In part of the session "Continuous Manufacturing and Publication of ICH Q13" at the PDA/FDA Joint Regulatory Conference, Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses how advanced manufacturing technology can improve things such as cost and efficiency.

Burridge: Manufacturing technologies such as continuous manufacturing, offer a number of benefits. Advantages of continuous manufacturing compared to other manufacturing include increased venture productivity, decreased capital cost, smaller cadence size and footprint and decreased cycle times or the ability to make product faster. You can also streamline your process flows with continuous manufacturing. There are several options if you'd like to increase your manufacturing output, you don't necessarily have to increase [imminent size]. Instead, you could run for a longer time. Or you could run at a higher mass flow rate. You also have the option to duplicate equipment not to scale out. Pharmaceutical quality assures the availability, safety and efficacy of every dose. This powerful yet simple statement, we hear a lot about safety and efficacy and rightly so. However, advanced manufacturing technologies such as continuous manufacturing, also have the potential to modernize pharmaceutical manufacturing and avoid or reduce drug shortages. I think drugs are of no use to patients if they're not available.

Editor's Note: The words in the [bracket] are an assumption of what is being said, as we have not gotten confirmation yet from the speaker about what exactly is being said.


Related to this article

TILE-X with NEBULA. Image courtesy of IMA Group.
The IMA Pharmaceutical and MedTech divisions will be highlighting the TILE-X fill-finish line, a new VPHP BioIndicator, X-PEN autoinjector platform, and a range of machines from its IMA Active, IMA Life, IMA Safe, and IMA BFB divisions at the CPHI Milan event.
Putting Sustainability to Work in Pharma
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
AAPS PharmSci 360: CMC Strategies, Part 2
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss navigating CMC requirements for new modalities and AI’s involvement in CMC.
AAPS PharmSci 360: CMC Strategies, Part 1
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.
Medical award concept, winner cup on the desk | Image Credit: ©BillionPhotos.com -stock.adobe.com
The finalists for the 2026 CPHI Pharma Awards span 15 categories including API development, digital transformation, manufacturing, supply chain, sustainability, and leadership, with winners revealed October 6 at CPHI Milan.